Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08

Rhea-AI Summary

Teladoc Health (NYSE:TDOC) announced an employment inducement award effective November 1, 2025 for new Chief Technology Officer Dave Ross. The grant includes 86,906 restricted stock units (RSUs) and 86,906 performance stock units (PSUs) at target (up to 173,812 shares if maximum is earned).

The RSUs vest with one-third on the first anniversary and the remainder quarterly over the next two years. The PSUs are earned over a three-year performance period based on specified financial metrics. The award was approved by the Compensation Committee and granted under the Teladoc Health 2023 Employment Inducement Incentive Award Plan as permitted by NYSE Rule 303A.08.

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee.

Effective November 1, 2025, in connection with commencing employment as Chief Technology Officer, Dave Ross was granted an award of restricted stock units covering 86,906 shares of Teladoc Health’s common stock, par value $0.001 per share (“Common Stock”), and an award of performance stock units covering a target of 86,906 shares of Common Stock (for which up to 173,812 shares may be earned). The restricted stock units vest, based on continued service to Teladoc Health, as to one-third of the underlying shares on the first anniversary of the grant date, with the remainder vesting quarterly over two years thereafter. The performance stock units provide a target number of shares of Common Stock that would be earned over three years based on various financial metrics. The award was approved by the Compensation Committee of the Board of Directors of Teladoc Health and was granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan as an employment inducement award pursuant to New York Stock Exchange Rule 303A.08.

About Teladoc Health

Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.

Media:
Lou Serio
202-569-9715
pr@teladochealth.com

FAQ

What did Teladoc Health (TDOC) grant Dave Ross as an inducement award on November 1, 2025?

He received 86,906 RSUs and 86,906 PSUs at target (up to 173,812 shares if maximum is earned).

What is the RSU vesting schedule for the TDOC inducement award to Dave Ross?

One-third vests on the first anniversary of the grant, with the remainder vesting quarterly over the following two years.

Over what period are the TDOC performance stock units for Dave Ross measured?

The PSUs are measured over a three-year performance period and vest based on specified financial metrics.

Under which plan and NYSE rule was the TDOC inducement award granted?

The award was granted under the Teladoc Health 2023 Employment Inducement Incentive Award Plan as an inducement award pursuant to NYSE Rule 303A.08.

How many total shares could be issued if Dave Ross's TDOC PSUs pay out at maximum?

If PSUs pay at maximum, up to 173,812 shares could be issued from the PSU component.

Who approved the inducement award for the new TDOC CTO and when did it take effect?

The Compensation Committee of the Board approved the award, which took effect on November 1, 2025.